CLINICAL_TRIALS
research
· 2018-07-24
Clinical Trial Update: Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia [Phase 2]
Summary
Phase 2 clinical trial evaluating Rituximab in combination with mVPDL for CD20-positive precursor cell lymphoblastic leukemia-lymphoma in adults.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Asan Medical Center | Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | Status: UNKNOWN